The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

@article{Padagas2005TheRA,
  title={The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism},
  author={Jen Padagas and Matthew Colloton and Victoria Shalhoub and Paul J. Kostenuik and Sean E Morony and Louis Munyakazi and Min Guo and D. Gianneschi and E. Shatzen and Zhaopo Geng and H.-L. Tan and Colin Robert Dunstan and David Lacey and Dominique Martin},
  journal={Calcified Tissue International},
  year={2005},
  volume={78},
  pages={35-44}
}
Osteoprotegerin (OPG) acts by neutralizing the receptor activator of nuclear factor-κB ligand (RANKL), the primary mediator of osteoclast differentiation, function, and survival. We examined whether OPG could affect the bone loss associated with chronic kidney disease (CKD) in a rodent model of CKD and secondary hyperparathyroidism (SHPT). SHPT was induced in rats by 5/6 nephrectomy (5/6 Nx) and a 1.2% P/0.6% Ca2+ diet. Starting 1 week after 5/6 Nx, rats were treated with vehicle (veh) or OPG… CONTINUE READING
12 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

  • I Avbersek-Luznik, BP Balon, I Rus, J Marc
  • J Clin Pharmacol
  • 2005

creased bone resorption in HD patients : is it caused by elevated RANKL synthesis ?

  • JC Huang, T Sakata, +4 authors RA Nissenson
  • Nephrol Dial Transplant
  • 2004

Similar Papers

Loading similar papers…